This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.
Read more
This article tells how a shareholder class action against Teva Pharmaceutical Industries, the largest generic drug maker in the world, ended the practice of hiding individual executive pay figures by companies crosslisted in Israel and the United States.
That practice relied on a tenuous reading of the law, according to which crosslisted issuers are exempt from the pay disclosure requirements in both countries. It had nevertheless persisted with no regulatory response because both countries maintained a hands-off attitude toward crosslisted companies. While the class action prompted Israel to ensure crosslisted issuers disclose individual executive pay, crosslisted issuers continue to be less transparent in other areas. The story serves as an important reminder of the powerful race to laxity in the global competition for securities listings.
Recent research shows that a high wage gap between managers and workers identifies better-performing firms, but the stock market does not seem to price...
We document a new channel through which a firm’s sustainability policies can contribute positively to its bottom line, by reducing labor costs and by...
Alibaba, the e-commerce giant that completed a record-setting IPO in the United States in 2014 and was valued at over $700 billion in early 2021, is one of...
We document that, over the last decade, the cross-sectional variation in CEO pay levels has declined precipitously, both at the economy level and within...